TABLE 3.
Chi‐squared analysis and Fisher's exact test for grade of increased creatinine
| Grade 1 | Grade 2 | p | Grade 1 | Grade 2 | p | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 0.81 | Type of endocrine therapy | 0.44 | ||||||
| <60 | 82 | 38 | AI | 65 | 28 | ||||
| ≥60 | 48 | 24 | Fulvestrant | 59 | 31 | ||||
| Weight (kg) | TAM | 3 | 3 | ||||||
| <68.5 | 91 | 37 | 0.16 | NA | 3 | 0 | |||
| ≥68.5 | 39 | 25 | Start dose of abemaciclib (mg/bid) | 0.33 | |||||
| Menopausal status a | 0.00 | 150 | 115 | 53 | |||||
| Premenopausal | 56 | 13 | 100 | 12 | 9 | ||||
| Postmenopausal | 74 | 49 | 50 | 3 | 0 | ||||
| Bone metastases status | 0.18 | Dose modifications | 0.18 | ||||||
| Yes | 53 | 19 | Yes | 24 | 6 | ||||
| No | 77 | 43 | No | 100 | 50 | ||||
| Osteoclast inhibitors | 0.28 | NA | 6 | 6 | |||||
| Bisphosphonate | 42 | 18 | |||||||
| Denosumab | 6 | 0 | |||||||
| Bisphosphonate/denosumab | 2 | 1 | |||||||
| None | 77 | 43 | |||||||
| NA | 3 | 0 |
Abbreviations: AI, aromatase inhibitors; bid, bis in die; NA, not access; TAM, tamoxifen.
The difference between groups is significant.